DUBLIN--(BUSINESS WIRE)--The "Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs" drug pipelines has been added to Research and Markets' offering.
The report Frontier Pharma: Ophthalmology Therapeutics Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative.
Ophthalmology pipeline has a highly active deals landscape. There were 271 licensing deals and 152 co-development deals completed between 2006 and 2016 across the therapy area, of which 94 licensing deals and 33 co-development deals had a disclosed value. Many products in the ophthalmology pipeline have previously been involved in licensing and co-development deals. Most of these are in the Preclinical stage of development, although many deals also took place for products at Phase II.
The pipeline contains a diverse range of molecular targets, and no single target dominates by any clear margin. However, products acting on components of the immune system largely cytokines and cytokine receptors and its regulatory signaling pathways make up the largest segment, followed by angiogenesis inhibitors. Generally, the composition by molecular target across the pipeline suggests that product development is shifting away from the type of therapies that currently dominate the market, indicating that the available therapeutic options could diversify.
Key Topics Covered:
1. List of Tables & Figures
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signaling Network, Disease Causation and Innovation Alignment
7 First-in-Class Target Evaluation
8 Deals and Strategic Consolidations
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ld3zvz/frontier_pharma
